ORIGINAL RESEARCH article
Front. Neurol.
Sec. Neuromuscular Disorders and Peripheral Neuropathies
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1571160
Malignancy in neuromuscular patients on chronic IVIG
Provisionally accepted
- 1University Health Network (UHN), Toronto, Canada
- 2Rambam Health Care Campus, Haifa, Haifa, Israel
- 3University Hospital Würzburg, Würzburg, Bavaria, Germany
- 4Mayo Clinic, Rochester, Minnesota, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Intravenous Immunoglobulin (IVIG) has been widely used to treat immune-mediated neuromuscular disorders. The relationship between IVIG and cancer is unclear. Preclinical studies have suggested that IVIG may influence cellular mechanisms pertinent to cancer development. This hypothesis is supported by clinical evidence, predominantly through case reports, although these findings are limited in scope and methodological rigor.Methods: A retrospective review was conducted on patients receiving chronic IVIG treatment for Myasthenia Gravis (MG) and chronic immune demyelinating polyradiculoneuropathy (CIDP), at our tertiary medical center between 2000 and 2023.Results: We identified 436 patients with MG and 102 patients with CIDP. Patients were divided into IVIG and non-IVIG treated in each of the disease groups. Seventy-five and 64 patients received IVIG in MG and CIDP groups, respectively. Cancer incidence was counted if it appeared at least one year after the diagnosis of MG or CIDP. In the MG group, cancer incidence was 12 / 75 (16%) among IVIG-treated patients compared to 87 / 350 (25%) in the MG-non-IVIG group (p=0.09). Excluding mild MG cases, who were treated only by pyridostigmine, cancer incidence in the MG-non-IVIG group increased to 72/250 (28.8%), significantly higher than in the IVIG-MG group, p= 0.01. For CIDP patients receiving IVIG, incidence of cancer was 6 / 59 (10%), while in the non-IVIG-treated CIDP group, it was 9 / 34 (26%) (p = 0.03). Analyzing all IVIG-treated patients together (of both disease groups) showed a negative correlation between "time on IVIG treatment" and cancer (p=0.001). Using logistic regression, we observed a negative coefficient for IVIG exposure (-0.03, p=0.004), indicating that an increase in time from diagnosis is associated with a decreased likelihood of developing cancer in the IVIG-treated group.Conclusions: Chronic IVIG therapy may be associated with a reduced incidence of cancer, particularly among patients with CIDP. Additionally, we found a negative correlation between duration of IVIG treatment and cancer incidence, suggesting a potential protective effect of long-term IVIG exposure. To our knowledge, this is the first study to explore the relationship between sustained IVIG therapy and long-term cancer risk in neuromuscular autoimmune diseases.
Keywords: Myasthenia Gravis, cidp, IVIg, Cancer, autoimmune disorders. 2
Received: 05 Feb 2025; Accepted: 29 May 2025.
Copyright: © 2025 Khateb, bahous, Abuzant and Shelly. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mohamed Khateb, University Health Network (UHN), Toronto, Canada
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.